MMR-deficiency and BRCA2/EGFR/NTRK mutations

por Gokare, Prashanth, Lulla, Amriti R., El-Deiry, Wafik S.
Publicado 2017

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

por Miller, Elizabeth, Lee, Hee Jin, Lulla, Amriti, Hernandez, Liz, Gokare, Prashanth, Lim, Bora
Publicado 2014

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

por Tian, Xiaobing, Ahsan, Nagib, Lulla, Amriti, Lev, Avital, Abbosh, Philip, Dicker, David T., Zhang, Shengliang, El-Deiry, Wafik S.
Publicado 2021

Role of Dopamine Receptors in the Anticancer Activity of ONC201()()

por Kline, Christina Leah B., Ralff, Marie D., Lulla, Amriti R., Wagner, Jessica M., Abbosh, Phillip H., Dicker, David T., Allen, Joshua E., El-Deiry, Wafik S.
Publicado 2017

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

por Lev, Avital, Lulla, Amriti R., Wagner, Jessica, Ralff, Marie D., Kiehl, Joshua B., Zhou, Yan, Benes, Cyril H., Prabhu, Varun V., Oster, Wolfgang, Astsaturov, Igor, Dicker, David T., El-Deiry, Wafik S.
Publicado 2017

LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers

por Lulla, Amriti R., Akli, Said, Karakas, Cansu, Ha, Min Jin, Fowlkes, Natalie W., Mitani, Yoshitsugu, Bui, Tuyen, Wang, Jing, Rao, Xiayu, Hunt, Kelly K., Meijer, Laurent, El-Naggar, Adel K., Keyomarsi, Khandan
Publicado 2021

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

por Prabhu, Varun V., Lulla, Amriti R., Madhukar, Neel S., Ralff, Marie D., Zhao, Dan, Kline, Christina Leah B., Van den Heuvel, A. Pieter J., Lev, Avital, Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Batchelor, Tracy T., Chi, Andrew S., Elemento, Olivier, Allen, Joshua E., El-Deiry, Wafik S.
Publicado 2017

Discovery and clinical introduction of first-in-class imipridone ONC201

por Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.
Publicado 2016

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

por Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.
Publicado 2021